RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RECOMBINANT INTERLEUKIN-2 IN CHRONIC UREMIC PATIENTS WHO ARE NONRESPONDERS TO HEPATITIS-B VACCINE

Authors
JUNGERS P DEVILLIER P SALOMON H CERISIER JE COUROUCE A
Citation
P. Jungers et al., RANDOMIZED PLACEBO-CONTROLLED TRIAL OF RECOMBINANT INTERLEUKIN-2 IN CHRONIC UREMIC PATIENTS WHO ARE NONRESPONDERS TO HEPATITIS-B VACCINE, Lancet, 344(8926), 1994, pp. 856-857
Citations number
10
Categorie Soggetti
Medicine, General & Internal
Journal title
Lancet → ACNP
ISSN journal
01406736
Volume
344
Issue
8926
Year of publication
1994
Pages
856 - 857
Database
ISI
SICI code
0140-6736(1994)344:8926<856:RPTORI>2.0.ZU;2-S
Abstract
Natural interleukin-2 at low dose has been reported to overcome the no n-responsiveness of patients with chronic uraemia to hepatitis B vacci ne. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 mu g of recombinant preS2-containing hep atitis B vaccine with human recombinant interleukin-2 (1 MU) or placeb o (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 mlU/mL or more (56 vs 68%) were similar in both groups. Our results do not co nfirm local injection of interleukin-2 as an effective immunoadjuvant to hepatitis B vaccine in uraemic patients.